Michaela Dan
Research Subjects
Research Interests
Michaela Dan has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Beata Kieć-Wilk
Unit of Rare Metabolic Diseases, Department of Pathophysiology, Jagiellonian University Medical College, 31-121 Krakow, Poland
1 shared publication - Christine Serratrice
Department of Internal Medicine of the Aged, University Hospital of Geneva, Geneva, Switzerland
1 shared publication - Magy Abdelwahab
Cairo University Pediatric Hospital, Kasr Alainy
1 shared publication - Paul Guijt
International Gaucher Alliance, London EC2A 4NE, UK
1 shared publication - Shoshana Revel-Vilk
Gaucher Unit, The Eisenberg R&D Authority, Shaare Zedek Medical Center, Jerusalem 9103102, Israel
1 shared publication
Latest Publications
- Open Access
- 27 January 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (3) , 842
Home Enzyme Replacement Therapy in Gaucher Disease: A Review
Since the early 1990s, Gaucher Disease has been a pioneering condition for home-based enzyme replacement therapy (ERT), marking a significant shift in patient care. Since then, many countries have adopted this approach. However, home ERT is not possible in all countries. Objectives: The aim of this article is to explore the implementation of home ERT for Gaucher disease, focusing on patient expectations, safety, compliance, economic benefits, and practical considerations. Methods: The PRISMA reporting protocol was followed, focusing on articles about home ERT for Gaucher Disease. Results: Twenty articles were analyzed in the review, revealing promising outcomes. Home ERT has consistently been shown to be safe, to improve patients’ quality of life, to reduce the utilization of hospital resources, and to pose no compliance issues. Conclusions: We believe it is essential to expand the availability of home ERT for Gaucher Disease to all countries where ERT is accessible. Based on the literature review, we present the conditions that must be met before starting home ERT programs.
- 27 January 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (3) , 842
Open AccessHome Enzyme Replacement Therapy in Gaucher Disease: A Review
Since the early 1990s, Gaucher Disease has been a pioneering condition for home-based enzyme replacement therapy (ERT), marking a significant shift in patient care. Since then, many countries have adopted this approach. However, home ERT is not possible in all countries. Objectives: The aim of this article is to explore the implementation of home ERT for Gaucher disease, focusing on patient expectations, safety, compliance, economic benefits, and practical considerations. Methods: The PRISMA reporting protocol was followed, focusing on articles about home ERT for Gaucher Disease. Results: Twenty articles were analyzed in the review, revealing promising outcomes. Home ERT has consistently been shown to be safe, to improve patients’ quality of life, to reduce the utilization of hospital resources, and to pose no compliance issues. Conclusions: We believe it is essential to expand the availability of home ERT for Gaucher Disease to all countries where ERT is accessible. Based on the literature review, we present the conditions that must be met before starting home ERT programs.